# Chord Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chord-therapeutics

- Industry: Biotechnology
- Headquarters: Geneva, Switzerland
- Website: www.chordtherapeutics.com
- Total disclosed funding: $16M
- Latest round: Series A (Oct 13, 2020)
- Investors on record: 2

## About

Chord Therapeutics SA is a biotechnology firm focused on developing innovative therapies for rare neurological disorders, aiming to address critical unmet medical needs through targeted treatment solutions.Founded in 2014 and headquartered in Geneva, Switzerland, Chord Therapeutics SA specializes in creating advanced therapeutic solutions for rare diseases. The company has engaged in three major deals to date, with the latest investment round being a Series A which raised USD 16.00 mn, led by Omega Funds on December 20, 2021. Notably, the firm was acquired by Merck KGaA in December 2021, marking a significant transition in its operational strategy.Chord Therapeutics designs and develops innovative treatments specifically targeted at rare and challenging neurological conditions. The company operates a proprietary therapeutic platform aimed at providing solutions that improve patients' quality of life, collaborating with healthcare providers primarily across Europe and North America to fill the gaps in existing treatment options.Chord Therapeutics generates revenue through strategic partnerships with healthcare institutions and pharmaceutical companies. Its business model focuses on direct sales agreements, allowing healthcare providers to acquire its treatments for distribution to patients diagnosed with rare neurological disorders. Pricing details are not publicly disclosed, but the company may also enter collaborative agreements to enhance its revenue streams.As part of its strategy for future growth, Chord Therapeutics plans to introduce new therapeutic products targeting rare neurological disorders, although specific release dates have not been shared. The company aims to expand its market presence in both Europe and North America while leveraging its recent funding of USD 16.00 mn to support these initiatives. Following its acquisition by Merck KGaA, Chord Therapeutics is positioned to enhance its capabilities and expand its reach within the pharmaceutical landscape.

## Funding rounds

- Series A, Oct 13, 2020, $16M — Omega Funds
- Seed, Jan 1, 2015 — Eclosion Ventures

## Investors

- Eclosion Ventures (https://capitalatlas.ai/funds/eclosion-ventures) — Seed
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A